My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

161.53 +1.47 (+0.92%)

Streaming Delayed Price Updated: 2:29 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

55 56 Next >

Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year ↗

April 03, 2025

FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support traditional approval.

Via Benzinga

Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval ↗

April 03, 2025

The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage.

Via Investor's Business Daily

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals ↗

April 01, 2025

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

Via Benzinga

The Top 3 Vanguard ETFs of 2025 (so Far) Share This 1 Striking Common Denominator ↗

March 30, 2025

Via The Motley Fool

Topics Bonds ETFs

Is the Market Bullish or Bearish on Novartis? ↗

February 26, 2025

Via Benzinga

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Technical Analysis observations. ↗

March 29, 2025

Exploring NOVARTIS AG-SPONSORED ADR's Technical Signals and Breakout Potential: Promising Signs: NOVARTIS AG-SPONSORED ADR Setting the Stage for a Breakout.

Via Chartmill

No Fear And No Panic After A 10% Correction = No Bottom ↗

March 28, 2025

In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off.

Via Talk Markets

Topics Stocks / Equities

FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool ↗

March 28, 2025

FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy.

Via Benzinga

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is an undervalued gem with solid fundamentals. ↗

March 26, 2025

NOVARTIS AG-SPONSORED ADR has caught the attention as a great value stock. NYSE:NVS excels in profitability, solvency, and liquidity, all while being very reasonably priced.

Via Chartmill

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

March 27, 2025

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease ↗

March 21, 2025

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.

Via Benzinga

Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders ↗

March 20, 2025

Monte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2.1B in milestone payments.

Via Benzinga

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy ↗

March 19, 2025

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.

Via Benzinga

The Best Vanguard ETF to Invest $1,000 in Right Now ↗

March 18, 2025

Via The Motley Fool

Topics ETFs

These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy? ↗

March 11, 2025

Via The Motley Fool

Topics ETFs Stocks

Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss ↗

March 06, 2025

Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support.

Via Benzinga

Novartis Earns Near-Best Overall Rating As Profit Growth Climbs ↗

March 05, 2025

Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday.

Via Investor's Business Daily

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) stands out as a stock that provides good value for the fundamentals it showcases. ↗

March 04, 2025

Uncover the potential of NOVARTIS AG-SPONSORED ADR, an undervalued stock. NYSE:NVS maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction ↗

March 04, 2025

Highly ranked Novartis is forming the right side of a long cup base with a buy point of 120.92. And it's literally running higher.

Via Investor's Business Daily

Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy ↗

March 03, 2025

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.

Via Benzinga

3 Dividend Stocks That Are No-Brainer Buys Right Now ↗

March 01, 2025

Via The Motley Fool

Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program ↗

February 26, 2025

A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not impose unconstitutional fines, takings, or compelled speech.

Via Benzinga

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects ↗

February 24, 2025

Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing...

Via Benzinga

This Kraft Heinz Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday ↗

February 13, 2025

Via Benzinga

Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal ↗

February 11, 2025

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its cardiovascular portfolio.

Via Benzinga

Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight ↗

February 07, 2025

A list of Super Bowl LIX commercials and the celebrities and athletes attached to star in the ads.

Via Benzinga

Topics Artificial Intelligence

Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them ↗

February 10, 2025

The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads.

Via Benzinga

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond ↗

February 03, 2025

Via The Motley Fool

Novartis Ag (NVS) Q4 2024 Earnings Call Transcript ↗

January 31, 2025

NVS earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

55 56 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition